Dosing and uses of Atrovent Nasal Spray (ipratropium intranasal)
Adult dosage forms and strengths
nasal spray
- 0.03%
- 0.06%
Rhinitis
Allergic/nonallergic rhinitis: 2 sprays (0.03%) per nostril BID/TId
Rhinitis due to common cold: 2 sprays (0.06%) per nostril TID/QId
Pediatric dosage forms and strengths
nasal spray
- 0.03%
- 0.06%
Rhinitis
<5 years: Safety & efficacy not established
5-12 years: 2 sprays (0.06%) in each nostril TId
>12 years: 2 sprays (0.06%) in each nostril TID/QId
Atrovent Nasal Spray (ipratropium intranasal) adverse (side) effects
1-10%
Headache (9.8%)
URI (9.8%)
Epistaxis (9%)
Pharyngitis (8.1%)
Nasal dryness/irritation/congestion (5.1%)
Taste perversion (4%)
Nausea (2.2%)
Warnings
Contraindications
Hypersensitivity
Cautions
BPH, narrow-angle glaucoma
Contact with eye can cause burning, precipitation of narrow angle glaucoma
Pregnancy and lactation
Pregnancy category: B
Lactation: Unknown whether distributed in breast milk
Pregnancy categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA: Information not available.
Pharmacology of Atrovent Nasal Spray (ipratropium intranasal)
Mechanism of action
Anticholinergic bronchodilator
Inhibits vagally mediated reflexes by antagonizing effects of acetylcholine
